PGEN
Price
$0.71
Change
+$0.02 (+2.90%)
Updated
Dec 18, 04:27 PM (EDT)
70 days until earnings call
ZVRA
Price
$8.28
Change
-$0.21 (-2.48%)
Updated
Dec 18, 04:37 PM (EDT)
72 days until earnings call
Ad is loading...

PGEN vs ZVRA

Header iconPGEN vs ZVRA Comparison
Open Charts PGEN vs ZVRABanner chart's image
Precigen
Price$0.71
Change+$0.02 (+2.90%)
Volume$20.69K
CapitalizationN/A
Zevra Therapeutics
Price$8.28
Change-$0.21 (-2.48%)
Volume$1K
CapitalizationN/A
PGEN vs ZVRA Comparison Chart
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. ZVRA commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Hold and ZVRA is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (PGEN: $0.69 vs. ZVRA: $8.48)
Brand notoriety: PGEN and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 134% vs. ZVRA: 78%
Market capitalization -- PGEN: $202.14M vs. ZVRA: $452.63M
PGEN [@Biotechnology] is valued at $202.14M. ZVRA’s [@Biotechnology] market capitalization is $452.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • PGEN’s TA Score: 3 bullish, 5 bearish.
  • ZVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both PGEN and ZVRA are a bad buy in the short-term.

Price Growth

PGEN (@Biotechnology) experienced а -11.64% price change this week, while ZVRA (@Biotechnology) price change was -4.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

PGEN is expected to report earnings on Feb 26, 2025.

ZVRA is expected to report earnings on Feb 28, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($453M) has a higher market cap than PGEN($202M). ZVRA YTD gains are higher at: 29.466 vs. PGEN (-48.493). ZVRA has higher annual earnings (EBITDA): -78.22M vs. PGEN (-136.11M). ZVRA has more cash in the bank: 89.4M vs. PGEN (28.6M). PGEN has less debt than ZVRA: PGEN (5.75M) vs ZVRA (59.9M). ZVRA has higher revenues than PGEN: ZVRA (24.5M) vs PGEN (3.96M).
PGENZVRAPGEN / ZVRA
Capitalization202M453M45%
EBITDA-136.11M-78.22M174%
Gain YTD-48.49329.466-165%
P/E RatioN/AN/A-
Revenue3.96M24.5M16%
Total Cash28.6M89.4M32%
Total Debt5.75M59.9M10%
FUNDAMENTALS RATINGS
PGEN vs ZVRA: Fundamental Ratings
PGEN
ZVRA
OUTLOOK RATING
1..100
5565
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9138
P/E GROWTH RATING
1..100
10028
SEASONALITY SCORE
1..100
23n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (51) in the null industry is in the same range as ZVRA (83). This means that PGEN’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (95) in the null industry is in the same range as PGEN (100). This means that ZVRA’s stock grew similarly to PGEN’s over the last 12 months.

ZVRA's SMR Rating (98) in the null industry is in the same range as PGEN (98). This means that ZVRA’s stock grew similarly to PGEN’s over the last 12 months.

ZVRA's Price Growth Rating (38) in the null industry is somewhat better than the same rating for PGEN (91). This means that ZVRA’s stock grew somewhat faster than PGEN’s over the last 12 months.

ZVRA's P/E Growth Rating (28) in the null industry is significantly better than the same rating for PGEN (100). This means that ZVRA’s stock grew significantly faster than PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENZVRA
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 7 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TENWX11.09N/A
N/A
Nuveen Emerging Markets Eq Idx W
JHSGX30.80-0.17
-0.55%
JHancock U.S. Growth R4
HBSGX28.37-0.32
-1.12%
Hartford Small Cap Growth HLS IB
PMPSX42.09-0.56
-1.31%
ProFunds Precious Metals UltraSector Svc
CRMAX11.23-0.16
-1.40%
CRM Small/Mid Cap Value Inv

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+2.46%
CRSP - PGEN
54%
Loosely correlated
+0.88%
NTLA - PGEN
52%
Loosely correlated
-1.87%
BEAM - PGEN
52%
Loosely correlated
-1.21%
ARWR - PGEN
51%
Loosely correlated
-0.45%
RCKT - PGEN
51%
Loosely correlated
+1.36%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with AXON. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+0.47%
AXON - ZVRA
33%
Loosely correlated
-2.09%
GOSS - ZVRA
33%
Poorly correlated
+1.71%
VCYT - ZVRA
33%
Poorly correlated
-2.52%
PGEN - ZVRA
32%
Poorly correlated
+2.46%
CRNX - ZVRA
31%
Poorly correlated
+1.35%
More